Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Cheng

Showing results (61-70 of 120) with videos related to

Pageof 12
Sort By:
Journal of Clinical Pharmacology|October 22, 2013
Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infectionJoseph M Custodio, Xiang Yin, Mischa Hepner, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 3, 2005
Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre studyHassane Izzedine, Jean Sebastien Hulot, Daniel Vittecoq, et al.
Toxicology Reports|February 23, 2026
Lack of genotoxicity and subchronic toxicity in safety assessment studies of a <i>Clostridium beijerinckii</i> formulationEsther J Yu, John Eid, Jaime Hernandez-Maldonado, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 27, 2018
Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed WomenSally Hodder, Kathleen Squires, Cissy Kityo, et al.
AIDS (London, England)|April 21, 2004
Renal safety of tenofovir in HIV treatment-experienced patientsHassane Izzedine, Corinne Isnard-Bagnis, Jean Sébastien Hulot, et al.
Pediatrics|November 15, 2023
Cardiovascular Follow-up of Patients Treated for MIS-CDayna Zimmerman, Mark Shwayder, Andrew Souza, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2026
Distinguishing Photoacoustic and Photothermal Neuron Stimulation Through Quantitative Mapping Spatiotemporal Field EvolutionDeming Li, Andrew Cheng, Xinrui Gong, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2017
Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1-Infected AdultsJoel E Gallant, Melanie Thompson, Edwin DeJesus, et al.
AIDS (London, England)|May 26, 2018
Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamidePaul E Sax, Edwin DeJesus, Gordon Crofoot, et al.
Mbio|December 19, 2023
Requirement of GrgA for <i>Chlamydia</i> infectious progeny production, optimal growth, and efficient plasmid maintenanceBin Lu, Yuxuan Wang, Wurihan Wurihan, et al.
Pageof 12

Showing results (61-70 of 120) with videos related to

Sort By:
Pageof 12
Journal of Clinical Pharmacology|October 22, 2013
Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infectionJoseph M Custodio, Xiang Yin, Mischa Hepner, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 3, 2005
Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre studyHassane Izzedine, Jean Sebastien Hulot, Daniel Vittecoq, et al.
Toxicology Reports|February 23, 2026
Lack of genotoxicity and subchronic toxicity in safety assessment studies of a <i>Clostridium beijerinckii</i> formulationEsther J Yu, John Eid, Jaime Hernandez-Maldonado, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 27, 2018
Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed WomenSally Hodder, Kathleen Squires, Cissy Kityo, et al.
AIDS (London, England)|April 21, 2004
Renal safety of tenofovir in HIV treatment-experienced patientsHassane Izzedine, Corinne Isnard-Bagnis, Jean Sébastien Hulot, et al.
Pediatrics|November 15, 2023
Cardiovascular Follow-up of Patients Treated for MIS-CDayna Zimmerman, Mark Shwayder, Andrew Souza, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2026
Distinguishing Photoacoustic and Photothermal Neuron Stimulation Through Quantitative Mapping Spatiotemporal Field EvolutionDeming Li, Andrew Cheng, Xinrui Gong, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2017
Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1-Infected AdultsJoel E Gallant, Melanie Thompson, Edwin DeJesus, et al.
AIDS (London, England)|May 26, 2018
Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamidePaul E Sax, Edwin DeJesus, Gordon Crofoot, et al.
Mbio|December 19, 2023
Requirement of GrgA for <i>Chlamydia</i> infectious progeny production, optimal growth, and efficient plasmid maintenanceBin Lu, Yuxuan Wang, Wurihan Wurihan, et al.
Pageof 12